747 Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors

747 Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors

Bibliographic Details
Main Authors: Joal D Beane, Yazan Samhouri, Brent A Hanks, John Hyngstrom, Sarah Weiss, Heidi Gillenwater, Yeonhee Kim, J Randolph Hecht, Bishwa J Ganguly, Hajime Hiraragi, Lucy Gong, Navid Nikoo
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items